Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells

Journal of the National Cancer Institute

Volumn 92, Issue 12, 2000, Pages 987-994

  Orr, Michael S ^a   O'Connor, Patrick M ^b   Kohn, Kurt W ^c  

^a Gene Logic Inc   (United States)

^b AGOURON PHARMACEUTICALS INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE PROTEIN; CISPLATIN; DOXORUBICIN; FLAVOPIRIDOL; FLUOROURACIL; METHOTREXATE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PACLITAXEL; PROTEIN TYROSINE KINASE;

ADULT; ARTICLE; BREAST EPITHELIUM; BREAST TUMOR; CANCER CHEMOTHERAPY; CELL GROWTH; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0034697631     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/92.12.987     Document Type: Article

References (30)

1. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998;1377:M25-37.
2. Kavanaugh WM, Williams LT. An alternative to SH2 domains for binding tyrosinephosphorylated proteins. Science 1994;266: 1862-5.
3. Cohen GB, Ren R, Baltimore D. Modular binding domains in signal transduction proteins. Cell 1995;80:237-48.
4. Ricci A, Lanfrancone L, Chiari R, Belardo G, Pertica C, Natali PG, et al. Analysis of protein -protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene 1995;11:1519-29.
5. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-6.
6. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-64.
7. Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F, et al. Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 1991;6:1189-94.
8. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987;237:178-82.
9. Ming XF, Burgering BM, Wennstrom S, Claesson-Welsh L, Heldin CH, Bos JL, et al. Activation of p70/p85 S6 kinase by a pathway independent of p21ras. Nature 1994;371:426-9.
10. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 1995;15:1182-91.
11. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
12. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992;10:1049-56.
13. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer [published erratum appears in N Engl J Med 1994;331:211]. N Engl J Med 1994;330:1260-6.
14. Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998; 90:1346-60.
15. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D. et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361-70.
16. Pegram MD, Finn RS, Arzoo K, Beryl M, Pietras RJ, Slamon DJ. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-47.
17. O'Connor PM, Ferris DK, Pagano M, Draetta G, Pines J, Hunter T, et al. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently. J Biol Chem 1993;268:8298-308.
18. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
19. Jones J, Lagasse LD, Karlan BY. Steroid hormonal independence of HER-2/neu mRNA expression in four human ovarian carcinoma cell lines. Gynecol Oncol 1994;55(3 Pt 1):421-6.
20. Sabbatini AR, Basolo F, Valentini P, Mattii L, Calvo S, Fiore L, et al. Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line with c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 1994;59:208-11.
21. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1993;24:85-95.
22. Salomon DS, Brandt R. Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19: 183-232.
23. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994;1198:165-84.
24. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999;59:1391-9.
25. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988;80:1605-11.
26. Kwok TT, Sutherland RM. Epidermal growth factor reduces resistance to doxorubicin. Int J Cancer 1991;49:73-6.
27. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991;51:4575-80.
28. Tzahar E, Pinkas-Kramarski R. Moyer JD, Klapper LN, Alroy I, Levkowitz G, et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 1997;16:4938-50.
29. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 1998;18:5042-51.
30. Harris LN, Yang L, Tang C, Yang D, Lupu R. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2. Clin Cancer Res 1998;4:1005-12.